• metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) 5
• mNSCLC - L2 - adenocarcinoma cell
• mNSCLC - L2 - all population 5
• mNSCLC - L2 - EGFR high
• mNSCLC - L2 - EGFR mutant 1
• mNSCLC - L2 - EGFR wild type
• mNSCLC - L2 - KRAS mutant
• mNSCLC - L2 - KRAS wild type
• mNSCLC - L2 - PDL1 negative 1
• mNSCLC - L2 - PDL1 positive 7
• non squamous cell - mNSCLC - L2
• non squamous - mNSCLC - L2 - all population 1
• non squamous - mNSCLC - L2 - EGFR mutant
• non squamous - mNSCLC - L2 - PDL1 positive
• non squamous - mNSCLC - L2 - wild type (WT)
• squamous cell - mNSCLC - L2
• squamous - mNSCLC - L2 - all population 1
• squamous - mNSCLC - L2 - PDL1 positive

 

• chemotherapy
• antifolates
• pralatrexate
• cyclin inhibitor
• abemaciclib based treatment
• abemaciclib plus BSC
• gene alteration target therapy
• BRAF gene alteration targeted therapy
• BRAF inhibitor
• combined BRAF-MEK inhibitors
• trametinib plus dabrafenib
• EGFR gene alteration
• osimertinib
• KRAS gene alteration targeted therapy
• sotorasib
• MET gene alteration targeted therapy
• capmatinib
• HER inhibitor
• EGFR inhibitor
• afatinib based treatment
• afatinib alone
• afatinib plus BSC
• afatinib plus paclitaxel
• dacomitinib
• erlotinib based treatment
• erlotinib alone
• erlotinib plus gemcitabine
• erlotinib plus pemetrexed
• tivantinib plus erlotinib
• gefitinib based treatment
• gefitinib alone
• gefitinib plus BSC
• gefitinib plus SoC (rechallenge)
• icotinib
• nimotuzumab based treatment
• nimotuzumab plus gefitinib
• immune chekpoint inhibitors
• anti-PD-(L)1
• atezolizumab based treatment
• atezolizumab alone
• avelumab based treatment
• avelumab alone
• durvalumab based treatment
• durvalumab alone
• durvalumab plus osimertinib
• nivolumab based treatment
• nivolumab alone
• pembrolizumab based treatment
• pembrolizumab alone
• pembrolizumab (10mg/kg)
• pembrolizumab (2mg/kg)
• Tislelizumab
• Immune checkpoint association
• durvalumab plus tremelimumab
• VEGF(R) inhibitor
• sorafenib
• vandetanib

• versus all
• vs chemotherapy
• vs antifolates
• vs pemetrexed
• vs non platinum-based chemotherapy
• vs nucleoside analogues (pyrimidine/purine)
• vs gemcitabine
• vs taxanes
• vs docetaxel
• vs platinum-based chemotherapy
• vs platinum derivate
• vs platinum association
• vs paclitaxel plus carboplatin
• vs pemetrexed plus platin
• vs Standard of Care (SoC)
• vs placebo plus SoC
• vs gene alteration target therapy
• vs EGFR gene alteration
• vs osimertinib
• vs HER inhibitor
• vs EGFR inhibitor
• vs erlotinib based treatment
• vs erlotinib alone
• vs Erlotinib plus BSC
• vs gefitinib based treatment
• vs gefitinib alone
• vs non active control
• vs no control (uncontrolled study)
• vs placebo
• vs placebo plus BSC
• vs VEGF(R) inhibitor
• vs bevacizumab based treatment
• vs bevacizumab plus docetaxel
• vs cabozantinib
• vs cabozantinib plus erlotinib
• vs sorafenib
• vs sorafenib and erlotinib

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)